Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion in Men with BPH-LUTS
2010-020220-22Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Tadalafil arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in prostatic transitional zone resistive index (RI) at Week 8. Started Jul 2010; status: completed.
02
Drugs
tadalafil
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2010-020220-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020220-22.